ReviewLancet (London, England)2025
Shigellosis.
Review in Lancet (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122.The Journal of infectious diseases · 2026Trial
- Review
- Antimicrobial Resistance Profiles of Bacterial Pathogens Associated with Acute Diarrheal Disease: A Three-Year Retrospective Study in a Romanian Tertiary-Care Hospital.Antibiotics (Basel, Switzerland) · 2026Article
- Identification of a novel mutation of sat (Gly82Arg) in Shigella flexneri serotype 7a: insights into clinical relevance.Folia microbiologica · 2026Article
- Epidemiological characteristics and spatio-temporal analysis of bacillary dysentery in Shaanxi Province, China, 2005-2024.BMC infectious diseases · 2026Article
- Characterization and genomic analysis of DSF2: a novel lytic phage infecting multidrug-resistantFrontiers in microbiology · 2026Article
- A dual functional inhibitory molecule to combat GyrA-ParC and associated mutants in fluoroquinolone-resistantFrontiers in bioinformatics · 2026Article
- Isolation and characterization of lyticFrontiers in cellular and infection microbiology · 2026Article
- Clinical outcomes of carbapenem vs. non-carbapenem therapy in hospitalized adults with shigellosis.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Utilizing rapid diagnostic tests in infectious disease surveillance and response in humanitarian emergencies.Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Shigella is a Gram-negative, facultative intracellular, gastric acid-resistant bacterium of the Enterobacteriaceae family, which includes four serogroups: Shigella dysenteriae, Shigella sonnei, Shigella flexneri, and Shigella boydii. Globally, shigellosis is the most common cause of invasive bloody diarrhoea in children younger than 5 years. Humans are the only natural reservoir and an inoculum of only 10-100 organisms is required for infection. Rising antibiotic resistance rates increasingly reduce the ability to adequately treat severe disease. The prevention of infection with vaccination and sanitation strategies remains a crucial step in reducing worldwide morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.